PRX 003

Drug Profile

PRX 003

Alternative Names: PRX003

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neotope Biosciences; Onclave Therapeutics
  • Developer Prothena; Prothena Corporation
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer
  • Discontinued Inflammation; Psoriasis

Most Recent Events

  • 29 Sep 2017 Discontinued - Phase-I for Psoriasis in USA (IV)
  • 29 Sep 2017 Discontinued - Preclinical for Inflammation in Ireland (Parenteral)
  • 29 Sep 2017 Efficacy and adverse events data from a phase Ib trial in Psoriasis released by Prothena Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top